Industries > Pharma > Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031
Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031
In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials
Visiongain has published a new Pharma Leader Series report on Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031. The global ophthalmic drugs manufacturers market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031.
Curious to know how hard the COVID-19 has Impacted the Competitor’s Revenue?
Buy this report to discover the impact of COVID-19 and the subsequent recession/ economic recovery on the ophthalmic drugs manufacturers. Establish which of the new mergers, acquisitions and collaborations are changing competitive dynamics today.
Are you in the global race? Where do you stand in the cut throat global competition?
The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key opportunities – what are they and how can you benefit? This report will tell you.
With product approvals over the next decade set to be a key issue facing all competitors in the market – you must discover the essential strategies being implemented by key market players between 2015 and Jan 2021.
To access the data contained in this document please email contactus@visiongain.com
Buy this report to find out analysis of strategies adopted by Top 50 players in the market to stay ahead for their competitor.
Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions. Products based on superior technology, particularly those technologies that increase clinical effectiveness or increase patient compliance, are more likely to succeed.
How this report will benefit you?
The 397-page report provides clear detailed insight into the ophthalmic drugs manufacturers market. Discover the global top 50 rankings, top business strategies adopted by the key players, product mapping, services provided, recent activities of the companies, key drivers and challenges affecting the market.
Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 397-page report you will receive 300+ tables and 200+ figures– all unavailable elsewhere.
By ordering and reading our brand-new report today you stay better informed and ready to act. Visiongain’s study is intended for anyone requiring commercial analyses for the top 50 ophthalmic drugs manufacturers market. You find data, trends and predictions.
Top 50 Companies Profiled in the Report
Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles
• Johnson & Johnson Vision Company
• Roche Holding AG (Roche)
• Pfizer
• Novartis AG
• Merck & Co.
• AbbVie Inc
• Takeda
• Essilor International S.A.
• Teva Pharmaceuticals
• Otsuka Pharmaceutical
• Bausch Health
• Alcon Inc.
• Regeneron Pharmaceuticals Inc.
• Edwards Lifesciences Corp
• Coopervision Company
• Santen Pharmaceuticals
• Rohto Pharmaceutical Co., Ltd.
• Carl Zeiss Meditec AG
Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles
• Topcon Corporation
• Veeva System Inc
• Recipharm AB
• Menicon co ltd.
• Chengdu Kanghong Pharmaceutical
• Beximco
• Glaukos Corporation
• Staar Surgicals
• Omeros
• Aerie Pharmaceuticals
• Hoya Corporation
• Alimera Sciences
• Bora Pharmaceuticals Co Ltd
• Iridex
• EyeGate Pharmaceuticals
• Kalvista Pharmaceuticals Inc
• Ellex Medical Lasers Ltd.
• Thrombo Genics NV
• EyeGate Pharmaceuticals
• OphthaliX /Wize Pharma
Top 10 Ophthalmic Drugs Manufacturing Companies to Watch
• Gensight Biologics
• Neurotech
• Phio Pharmaceuticals Corp
• Kubota Pharmaceutical Holdings Co Ltd
• Aerpio Therapeutics
• Ampio Pharmaceuticals
• Kodiak Sciences Inc
• Opsis Therapeutics
• Grevis Pharmaceutical
• The Innovexia Life Sciences
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031: In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1.1 Scope of Report
1.2 Reasons For Doing The Report
1.3 Why You Should Buy This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.8 Market Evaluation & Forecasting Methodology
1.9 COIVD-19 Impact Recovery Pattern Analysis
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2 Executive Summary
2.1 Global Incidence of Eye Disease Continues To Grow
2.2 High Unmet Clinical Need Remains To Develop Safer, More Efficacious Treatments With Patient-Friendly Formulations.
2.3 AMD is A Major Cause of Blindness in Older People
2.4 Glaucoma Affects More Than 60 Million People Worldwide
2.5 DES is Another Prevalent Age-Related Condition
2.6 Uveitis Affects Up To 50 Million People Worldwide And Is The Main Cause Of Sight Loss
2.7 The Recent Advances Driving The Field Forward, Patient Demographics And Market Trends
2.8 COVID-19 Impact on Ophthalmic Drug Manufacturers Market
3 Ophthalmic Drugs Market Overview
3.1 Retinal Diseases
3.2 Age-Related Macular Degeneration (AMD)
3.2.1 Disease Subtypes
3.2.2 Market Drivers for Dry AMD
3.2.3 Areas Of Unmet Clinical Need
3.2.4 New Therapies For Wet AMD
3.2.5 New Treatments For Dry AMD
3.2.6 New Therapies
3.2.7 Future Market Size
3.3 GLAUCOMA
3.3.1 Disease Subtypes
3.3.2 Diagnosis Rate
3.3.3 Current Treatment
3.3.4 Fixed Dose Combinations
3.3.5 Market Drivers
3.3.6 Areas Of Unmet Clinical Need
3.3.7 New Delivery Approaches And Formulations
3.3.8 New Therapies
3.4 Dry Eye Syndrome
3.4.1 Diagnosis Rate
3.4.2 Current Treatment
3.4.3 Market Drivers
3.4.4 Areas Of Unmet Clinical Need
3.4.5 New Therapies
3.4.6 New Formulations
3.4.7 Early-Stage Drug Development
3.5 UVEITIS
3.5.1 Diagnosis Rate
3.5.2 Current Treatment
3.5.3 Market Drivers
3.5.4 Areas Of Unmet Clinical Need
3.5.5 New Therapies
3.5.6 New Formulations
3.5.7 Early-Stage Drug Development
4 Market Dynamics
4.1 Factors Affecting Growth
4.1.1 How Product and Process Innovation Is Driving the Market?
4.1.2 Continuing Focus on Productivity, will It Boost the Sales?
4.1.3 Development Of New Drugs Carries More Risks
4.1.4 Why Stringent Regulations Are Important?
4.1.5 How Hard is It to Tackle Patent Expirations?
4.1.6 How Decreasing Research and Development Success Rates Affects the Market Growth?
4.2 Market Drivers
4.2.1 Why Ophthalmic Biosimilar Are Gaining Tractions in the Global Market?
4.2.2 Increased Focus on Orphan and Specialty Drugs Boosting Research and Sales
4.2.3 Generics: A Driver or Restraint?
4.2.4 Increasing Demand for Formulation Development Services
4.2.5 Ophthalmic Drug Manufacturers’ Move Toward Strategic Collaboration With Drug Delivery Technology Companies
4.3 Opportunities in the Global Market
4.3.1 Lack of Manufacturing and Packaging Capabilities
4.3.2 Pharma Companies Will Continue to Look For Ways To Cut Drug Costs
4.3.3 Need for New Drug Delivery Technologies
4.3.4 Chemical APIs Will Experience Resurgence after the Shift of Focus to Biological APIs
4.4 Growth Restrain
4.4.1 Backwards Integration for Generics Manufacturers
4.4.2 The US Generic Drug User Fee Act and API Manufacturing
4.4.3 Challenges in Contract Manufacturing
4.4.4 Challenges in Assessing the Market: Supply versus Demand
4.5 SWOT Analysis
4.6 Porter’s Five Forces Analysis
4.6.1 What is Porter Five (5) Forces
4.6.2 Threat of New Entrants (Low to Moderate)
4.6.3 Rivalry Among the Existing Players (High)
4.6.4 Bargaining Power of Suppliers (Low)
4.6.5 Threats from Substitute Products (Low to Moderate)
4.6.6 Bargaining Power of Buyers (High)
5 Global Ophthalmic Drug Manufacturer Market
5.1 Overview
5.1.1 Analysis of Market Status Before COVID-19
5.1.2 Analysis of Market V-Shaped Recovery Pattern
5.1.3 Analysis of Market W-Shaped Recovery Pattern
5.1.4 Analysis of Market U-Shaped Recovery Pattern
5.1.5 Analysis of Market L-Shaped Recovery Pattern
5.2 Regional Market Overview
5.2.1 Analysis of Market Status Before COVID-19
5.2.2 Analysis of Market V-Shaped Recovery Pattern
5.2.3 Analysis of Market W-Shaped Recovery Pattern
5.2.4 Analysis of Market U-Shaped Recovery Pattern
5.2.5 Analysis of Market L-Shaped Recovery Pattern
6 Competitive Landscape
6.1 Strategy and Tactics: The Importance of Outsourcing Wisely
7 Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles
7.1 Why We Have Chosen These Companies
7.2 Johnson & Johnson Vision Company
7.2.1 Company Snapshot
7.2.2 Company Overview
7.2.3 Company Product Benchmarking
7.2.4 Company Financial Profile
7.2.5 Company Recent Developments
7.2.6 Company SWOT Analysis
7.2.7 Company Key Competitors in the Global Ophthalmic Market
7.2.8 Company Future Outlook
7.3 F. Hoffmann-La Roche AG Company
7.3.1 Company Snapshot
7.3.2 Company Overview
7.3.3 Company Product Benchmarking
7.3.4 Company Financial Profile
7.3.5 Company Recent Developments
7.3.6 Company SWOT Analysis
7.3.7 Company Key Competitors in the Global Ophthalmic Market
7.3.8 Company Future Outlook
7.4 Pfizer Pharmaceutical Company
7.4.1 Company Snapshot
7.4.2 Company Overview
7.4.3 Company Product Benchmarking
7.4.4 Company Financial Profile
7.4.5 Company Recent Developments
7.4.6 Company SWOT Analysis
7.4.7 Company Key Competitors in the Global Ophthalmic Market
7.4.8 Company Future Outlook
7.5 Novartis International AG Company
7.5.1 Company Snapshot
7.5.2 Company Overview
7.5.3 Company Product Benchmarking
7.5.4 Company Financial Profile
7.5.5 Company Recent Developments
7.5.6 Company SWOT Analysis
7.5.7 Company Key Competitors in the Global Ophthalmic Market
7.5.8 Company Future Outlook
7.6 Merck & Co. Pharmaceutical Company
7.6.1 Company Snapshot
7.6.2 Company Overview
7.6.3 Company Product Benchmarking
7.6.4 Company Financial Profile
7.6.5 Company Recent Developments
7.6.6 Company SWOT Analysis
7.6.7 Company Key Competitors in the Global Ophthalmic Market
7.6.8 Company Future Outlook
7.7 Allergan Pharmaceutical (Abbvie Inc) Company
7.7.1 Company Snapshot
7.7.2 Company Overview
7.7.3 Company Product Benchmarking
7.7.4 Company Financial Profile
7.7.5 Company Recent Developments
7.7.6 Company SWOT Analysis
7.7.7 Company Key Competitors in the Global Ophthalmic
7.7.8 Company Future Outlook
7.8 Takeda Pharmaceutical Company
7.8.1 Company Snapshot
7.8.2 Company Overview
7.8.3 Company Product Benchmarking
7.8.4 Company Financial Profile
7.8.5 Company Recent Developments
7.8.6 Company SWOT Analysis
7.8.7 Company Key Competitors in the Global Ophthalmic Market
7.8.8 Company Future Outlook
7.9 Essilor International S.A. Company
7.9.1 Company Snapshot
7.9.2 Company Overview
7.9.3 Company Product Benchmarking
7.9.4 Company Financial Profile
7.9.5 Company Recent Developments
7.9.6 Company SWOT Analysis
7.9.7 Company Key Competitors in the Global Ophthalmic Market
7.9.8 Company Future Outlook
7.10 Teva Pharmaceuticals Company
7.10.1 Company Snapshot
7.10.2 Company Overview
7.10.3 Company Product Benchmarking
7.10.4 Company Financial Profile
7.10.5 Company Recent Developments
7.10.6 Company SWOT Analysis
7.10.7 Company Key Competitors in the Global Ophthalmic Market
7.10.8 Company Future Outlook
7.11 Otsuka Pharmaceutical Company
7.11.1 Company Snapshot
7.11.2 Company Overview
7.11.3 Company Product Benchmarking
7.11.4 Company Financial Profile
7.11.5 Company Recent Developments
7.11.6 Company SWOT Analysis
7.11.7 Company Key Competitors in the Global Ophthalmic Market
7.11.8 Company Future Outlook
7.12 Bausch Health Company
7.12.1 Company Snapshot
7.12.2 Company Overview
7.12.3 Company Product Benchmarking
7.12.4 Company Financial Profile
7.12.5 Company Recent Developments
7.12.6 Company SWOT Analysis
7.12.7 Company Key Competitors in the Global Ophthalmic Market
7.12.8 Company Future Outlook
7.13 Alcon Inc Company
7.13.1 Company Snapshot
7.13.2 Company Overview
7.13.3 Company Product Benchmarking
7.13.4 Company Financial Profile
7.13.5 Company Recent Developments
7.13.6 Company SWOT Analysis
7.13.7 Company Key Competitors in the Global Ophthalmic Market
7.13.8 Company Future Outlook
7.14 Regeneron Pharmaceuticals Inc. Company
7.14.1 Company Snapshot
7.14.2 Company Overview
7.14.3 Company Product Benchmarking
7.14.4 Company Financial Profile
7.14.5 Company Recent Developments
7.14.6 Company SWOT Analysis
7.14.7 Company Key Competitors in the Global Ophthalmic Market
7.14.8 Company Future Outlook
7.15 Recipharm publ AB Company
7.15.1 Company Snapshot
7.15.2 Company Overview
7.15.3 Company Product Benchmarking
7.15.4 Company Financial Profile
7.15.5 Company Recent Developments
7.15.6 Company SWOT Analysis
7.15.7 Company Key Competitors in the Global CMO Market
7.15.8 Company Future Outlook
7.16 Beximco Pharmaceuticals Limited Company
7.16.1 Company Snapshot
7.16.2 Company Overview
7.16.3 Company Financial Profile
7.16.4 Company Product Benchmarking
7.16.5 Company Recent Developments
7.16.6 Company SWOT Analysis
7.16.7 Company Key Competitors in the Global Ophthalmic Market
7.17 Edwards Lifesciences Company
7.17.1 Company Snapshot
7.17.2 Company Overview
7.17.3 Company Product Benchmarking
7.17.4 Company Financial Profile
7.17.5 Company Recent Developments
7.17.6 Company SWOT Analysis
7.17.7 Company Key Competitors in the Global Ophthalmic Market
7.17.8 Company Future Outlook
7.18 Cooper vision Company
7.18.1 Company Snapshot
7.18.2 Company Overview
7.18.3 Company Product Benchmarking
7.18.4 Company Financial Profile
7.18.5 Company Recent Developments
7.18.6 Company SWOT Analysis
7.18.7 Company Key Competitors in the Global Ophthalmic Market
7.19 Santen Pharmaceuticals Company
7.19.1 Company Snapshot
7.19.2 Company Overview
7.19.3 Company Product Benchmarking
7.19.4 Company Financial Profile
7.19.5 Company Recent Developments
7.19.6 Company SWOT Analysis
7.19.7 Company Key Competitors in the Global Ophthalmic Market
7.20 Rohto Pharmaceutical Company
7.20.1 Company Snapshot
7.20.2 Company Overview
7.20.3 Company Product Benchmarking
7.20.4 Company Financial Profile
7.20.5 Company Recent Developments
7.20.6 Company SWOT Analysis
7.20.7 Company Key Competitors in the Global Ophthalmic Market
7.21 Carl zeiss meditech AG Company
7.21.1 Company Snapshot
7.21.2 Company Overview
7.21.3 Company Product Benchmarking
7.21.4 Company Financial Profile
7.21.5 Company Recent Developments
7.21.6 Company SWOT Analysis
7.21.7 Company Key Competitors in the Global Ophthalmic Market
7.21.8 Company Future Outlook
8 Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles
8.1 Why We Have Chosen These Companies?
8.2 Topcon Corporation Company
8.2.1 Company Snapshot
8.2.2 Company Overview
8.2.3 Company Product Benchmarking
8.2.4 Company Financial Profile
8.2.5 Company Recent Developments
8.2.6 Company SWOT Analysis
8.2.7 Company Key Competitors in the Global Ophthalmic Market
8.2.8 Company Future Outlook
8.3 Veeva System Inc Company
8.3.1 Company Snapshot
8.3.2 Company Overview
8.3.3 Company Product Benchmarking
8.3.4 Company Financial Profile
8.3.5 Company Recent Developments
8.3.6 Company SWOT Analysis
8.3.7 Company Key Competitors in the Global Ophthalmic Market
8.3.8 Company Future Outlook
8.4 Menicon co ltd. Company
8.4.1 Company Snapshot
8.4.2 Company Overview
8.4.3 Company Product Benchmarking
8.4.4 Company Financial Profile
8.4.5 Company Recent Developments
8.4.6 Company SWOT Analysis
8.4.7 Company Key Competitors in the Global Ophthalmic Market
8.4.8 Company Future Outlook
8.5 Chengdu Kanghong Pharmaceuticals Company
8.5.1 Company Snapshot
8.5.2 Company Overview
8.5.3 Company Product Benchmarking
8.5.4 Company Financial Profile
8.5.5 Company Recent Developments
8.5.6 Company SWOT Analysis
8.5.7 Company Key Competitors in the Global Ophthalmic Market
8.6 Nidek Co. Ltd Company
8.6.1 Company Snapshot
8.6.2 Company Overview
8.6.3 Company Product Benchmarking
8.6.4 Company Recent Developments
8.6.5 Company SWOT Analysis
8.6.6 Company Key Competitors in the Global Ophthalmic Market
8.6.7 Company Future Outlook
8.7 Glaukos Corporation Company
8.7.1 Company Snapshot
8.7.2 Company Overview
8.7.3 Company Product Benchmarking
8.7.4 Company Financial Profile
8.7.5 Company Recent Developments
8.7.6 Company SWOT Analysis
8.7.7 Company Key Competitors in the Global Ophthalmic Market
8.7.8 Company Future Outlook
8.8 Staar Surgical Company
8.8.1 Company Snapshot
8.8.2 Company Overview
8.8.3 Company Product Benchmarking
8.8.4 Company Financial Profile
8.8.5 Company Recent Developments
8.8.6 Company SWOT Analysis
8.8.7 Company Key Competitors in the Global Ophthalmic Market
8.9 Omeros Corporation Company
8.9.1 Company Snapshot
8.9.2 Company Overview
8.9.3 Company Product Benchmarking
8.9.4 Company Financial Profile
8.9.5 Company Recent Developments
8.9.6 Company SWOT Analysis
8.9.7 Company Key Competitors in the Global Ophthalmic Market
8.10 Aeries pharmaceuticals Company
8.10.1 Company Snapshot
8.10.2 Company Overview
8.10.3 Company Product Benchmarking
8.10.4 Company Financial Profile
8.10.5 Company Recent Developments
8.10.6 Company SWOT Analysis
8.10.7 Company Key Competitors in the Global Ophthalmic Market
8.11 Hoya Corporation Company
8.11.1 Company Snapshot
8.11.2 Company Overview
8.11.3 Company Product Benchmarking
8.11.4 Company Financial Profile
8.11.5 Company SWOT Analysis
8.11.6 Company Key Competitors in the Global Ophthalmic Market
8.11.7 Company Future Outlook
8.12 HORAMA Company
8.12.1 Company Snapshot
8.12.2 Company Overview
8.12.3 Company Product Benchmarking
8.12.4 Company Recent Developments
8.12.5 Company SWOT Analysis
8.12.6 Company Key Competitors in the Global Ophthalmic Market
8.12.7 Company Future Outlook
8.13 Alimera science Company
8.13.1 Company Snapshot
8.13.2 Company Overview
8.12.3 Company Product Benchmarking
8.12.4 Company Financial Profile
8.13.5 Company Recent Developments
8.13.6 Company SWOT Analysis
8.13.7 Company Key Competitors in the Global Ophthalmic Market
8.13.8 Company Future Outlook
8.14 Bora Pharmaceuticals Company
8.14.1 Company Snapshot
8.14.2 Company Overview
8.14.3 Company Product Benchmarking
8.14.4 Company Financial Profile
8.14.5 Company Recent Developments
8.14.6 Company SWOT Analysis
8.14.7 Company Key Competitors in the Global Ophthalmic Market
8.14.8 Company Future Outlook
8.15 Iridex Corporation Company
8.15.1 Company Snapshot
8.15.2 Company Overview
8.15.3 Company Product Benchmarking
8.15.4 Company Financial Profile
8.15.5 Company Recent Developments
8.15.6 Company SWOT Analysis
8.15.7 Company Key Competitors in the Global Ophthalmic Market
8.15.8 Company Future Outlook
8.16 Eyepoint Pharmaceutical Company
8.16.1 Company Snapshot
8.16.2 Company Overview
8.16.3 Company Product Benchmarking
8.16.4 Company Financial Profile
8.16.5 Company Recent Developments
8.16.6 Company SWOT Analysis
8.16.7 Company Key Competitors in the Global Ophthalmic Market
8.17 Kalvista Pharmaceuticals Inc Company
8.17.1 Company Snapshot
8.17.2 Company Overview
8.17.3 Company Product Benchmarking
8.17.4 Company Financial Profile
8.17.5 Company SWOT Analysis
8.17.6 Company Key Competitors in the Global Ophthalmic Market
8.17.7 Company Future Outlook
8.18 Ellex Medical Lasers Ltd. Company (Nova Eye Medical)
8.18.1 Company Snapshot
8.18.2 Company Overview
8.18.3 Company Product Benchmarking
8.18.4 Company Financial Profile
8.18.5 Company SWOT Analysis
8.18.6 Company Key Competitors in the Global Ophthalmic Market
8.18.7 Company Future Outlook
8.19 Oxurion NV Company (ThromboGenics)
8.19.1 Company Snapshot
8.19.2 Company Overview
8.19.3 Company Product Benchmarking
8.19.4 Company Financial Profile
8.19.5 Company SWOT Analysis
8.19.6 Company Key Competitors in the Global Ophthalmic Market
8.19.7 Company Future Outlook
8.20 EyeGate Pharmaceuticals Company
8.20.1 Company Snapshot
8.20.2 Company Overview
8.20.3 Company Product Benchmarking
8.20.4 Company Financial Profile
8.20.5 Company Recent Developments
8.20.6 Company SWOT Analysis
8.20.7 Company Key Competitors in the Global Ophthalmic Market
8.20.8 Company Future Outlook
8.21 Ophthalix, Inc (Wize Pharma Inc) Company
8.21.1 Company Snapshot
8.21.2 Company Overview
8.21.3 Company Product Benchmarking
8.21.4 Company Financial Profile
8.21.5 Company Recent Developments
8.21.6 Company SWOT Analysis
8.21.7 Company Key Competitors in the Global Ophthalmic Market
9 Top 10 Ophthalmic Drugs Manufacturing Companies to Watch
9.1 Why We Have Chosen These Companies?
9.2 GenSight Biologics Company
9.2.1 Company Snapshot
9.2.2 Company Overview
9.2.3 Company Product Benchmarking
9.2.4 Company Financial Profile
9.2.5 Company Recent Developments
9.2.6 Company SWOT Analysis
9.2.7 Company Key Competitors in the Global Ophthalmic Market
9.3 Neurotech Pharmaceuticals Inc Company
9.3.1 Company Snapshot
9.3.2 Company Overview
9.3.3 Company Product Benchmarking
9.3.4 Company SWOT Analysis
9.3.5 Company Key Competitors in the Global Ophthalmic Market
9.4 Phio Pharmaceuticals Company
9.4.1 Company Snapshot
9.4.2 Company Overview
9.4.3 Company Product Benchmarking
9.4.4 Company Financial Profile
9.4.5 Company Recent Developments
9.4.6 Company SWOT Analysis
9.4.7 Company Key Competitors in the Global Ophthalmic Market
9.4.8 Company Future Outlook
9.5 Kubota Pharmaceutical Holdings Co Ltd Company
9.5.1 Company Snapshot
9.5.2 Company Overview
9.5.3 Company Product Benchmarking
9.5.4 Company Financial Profile
9.5.5 Company Recent Developments
9.5.6 Company SWOT Analysis
9.5.7 Company Key Competitors in the Global Ophthalmic Market
9.6 Aerpio Therapeutics Company
9.6.1 Company Snapshot
9.6.2 Company Overview
9.6.3 Company Product Benchmarking
9.6.4 Company Financial Profile
9.6.5 Company Recent Developments
9.6.6 Company SWOT Analysis
9.6.7 Company Key Competitors in the Global Ophthalmic Market
9.6.8 Company Future Outlook
9.7 Ampio Pharmaceuticlas Company
9.7.1 Company Snapshot
9.7.2 Company Overview
9.7.3 Company Product Benchmarking
9.7.4 Company Financial Profile
9.7.5 Company Recent Developments
9.7.6 Company SWOT Analysis
9.7.7 Company Key Competitors in the Global Ophthalmic Market
9.8 Kodiak Sciences Company
9.8.1 Company Snapshot
9.8.2 Company Overview
9.8.3 Company Product Benchmarking
9.8.4 Company Financial Profile
9.8.5 Company Recent Developments
9.8.6 Company SWOT Analysis
9.8.7 Company Key Competitors in the Global Ophthalmic Market
9.8.8 Company Future Outlook
9.9 Opsis Therapeutics Company
9.9.1 Company Snapshot
9.9.2 Company Overview
9.9.3 Company Product Benchmarking
9.9.4 Company SWOT Analysis
9.9.5 Company Key Competitors in the Global Ophthalmic Market
9.10 Grevis Pharmaceuticals Company
9.10.1 Company Snapshot
9.10.2 Company Overview
9.10.3 Company Product Benchmarking
9.10.4 Company SWOT Analysis
9.10.5 Company Key Competitors in the Global Ophthalmic Market
9.10.6 Company Future Outlook
9.11 Innovexia Lifesciences Company
9.11.1 Company Snapshot
9.11.2 Company Overview
9.11.3 Company Product Benchmarking
9.11.4 Company SWOT Analysis
9.11.5 Company Key Competitors in the Global Ophthalmic Market
9.11.6 Company Future Outlook
10 Conclusion and Recommendations
10.1 Recommendations
11 Glossary
List of Tables
Table 1. Global Ophthalmic Drug Manufacturer Market Summary Table
Table 2. Products Approved To Treat Wet AMD
Table 3. Global AMD Sales Of Approved Products By Company, Through 2019 ($ Millions)
Table 4. Global Market Share Of AMD Approved Products By Company, 2019
Table 5. Areas Of Unmet Clinical Need In Amd Treatment
Table 6. Products In Development For Wet AMD – Phase Iii
Table 7. Products In Development For Wet AMD - Phase II
Table 8. Products In Development For Wet AMD - Phase I
Table 9. Products In Development For Dry AMD - Phase III
Table 10. Products In Development For Dry AMD - Phase II
Table 11. Global AMD Sales Of Pipeline Products, 2019 ($ Millions)
Table 12. Approved Glaucoma Drug Characteristics
Table 13. Products Approved To Treat Glaucoma – Monotherapy
Table 14. Products Approved To Treat Glaucoma - Fixed Dose Combinations
Table 15. Prescription Drug Classes In The U.S., 2019
Table 16. Prescription Drug Classes In Europe, 2019
Table 17. Prescription Drug Classes In Japan, 2019
Table 18. Global Glaucoma Sales Of Approved Products, Through 2020 ($ Millions)
Table 19. Global Glaucoma Sales Of Approved Products By Drug Class, Through 2019 ($ Millions)
Table 20. Global Market Share Of Glaucoma Approved Products By Drug Class
Table 21. Global Glaucoma Sales Of Approved Products By Company, Through 2019 ($ Millions)
Table 22. Global Market Share Of Glaucoma Approved Products By Company, 2014
Table 23. Areas Of Unmet Clinical Need In Glaucoma Treatment
Table 24. Products In Development To Treat Glaucoma - Phase III
Table 25. Products In Development To Treat Glaucoma - Phase II
Table 26. Products In Development To Treat Glaucoma - Phase I
Table 27. Rock Inhibitors In Development
Table 28. Gene Silencing Agents In Development
Table 29. Global Glaucoma Sales Of Pipeline Products, Through 2020 ($ Millions)
Table 30. Products Approved To Treat DES
Table 31. Global DES Sales Of Approved Products, 2020 ($ Millions)
Table 32. Global Des Sales Of Approved Products By Drug Class, 2020 ($ Millions)
Table 33. GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2020 (%)
Table 34. Global DES Sales Of Approved Products By Company, 2020 ($ Millions)
Table 35. Global Market Share Of Des Approved Products By Company, 2020, (%)
Table 36. Areas Of Unmet Clinical Need In Des Treatment
Table 37. Products In Development To Treat Des - Phase III
Table 38. Products In Development To Treat Des - Phase II
Table 39. Global Des Sales Of Pipeline Products, 2020 ($ Millions)
Table 40. Products Approved To Treat UVEITIS
Table 41. Global UVEITIS Sales Of Approved Products, 2020, ($ Millions)
Table 42. Global UVEITIS Sales Of Approved Products By Company, 2020, ($ Millions)
Table 43. Global Market Share Of UVEITIS Approved Products By Company, 2020
Table 44. Areas Of Unmet Clinical Need In Uveitis Treatment
Table 45. Products In Development To Treat UVEITIS - Phase III
Table 46. Products In Development To Treat UVEITIS - Phase Ii
Table 47. Products In Development To Treat UVEITIS - Phase I
Table 48. Global Uveitis Sales Of Pipeline Products, 2020 ($ Millions)
Table 49. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 50. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 51. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 52. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 53. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 54. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 55. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 56. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 57. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 58. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 59. Johnson & Johnson Vision: Company Information
Table 60. Johnson & Johnson Vision: Company Product and Service Offerings
Table 61. Johnson & Johnson Vision: Company Product Pipeline
Table 62. Johnson & Johnson Vision: Company Financial Strengths Analysis 2019 (US$ Million)
Table 63. Johnson & Johnson Vision: Company Growth Share Analysis 2019 (%)
Table 64. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
Table 65. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
Table 66. F. Hoffmann-La Roche AG: Company Information
Table 67. F. Hoffmann-La Roche AG: Company Product and Service Offerings
Table 68. F. Hoffmann-La Roche AG: Company Product Pipeline
Table 69. F. Hoffmann-La Roche AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 70. F. Hoffmann-La Roche AG : Company Growth Share Analysis 2019 (%)
Table 71. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
Table 72. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
Table 73. Pfizer Pharmaceutical: Company Information
Table 74. Pfizer Pharmaceutical: Company Product and Service Offerings
Table 75. Pfizer Pharmaceuticals: Company Product Pipeline
Table 76. Pfizer Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 77. Pfizer Pharmaceutical: Company Growth Share Analysis 2019 (%)
Table 78. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
Table 79. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
Table 80. Novartis AG: Company Information
Table 81. Novartis AG: Company Product and Service Offerings
Table 82. Novartis AG: Company Product Pipeline
Table 83. Novartis AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 84. Novartis AG: Company Growth Share Analysis 2019 (%)
Table 85. Novartis AG: Company Recent Developments till Jan, 2021
Table 86. Novartis AG: Company Recent Developments till Jan, 2021
Table 87. Merck & Co., Inc: Company Information
Table 88. Merck & Co., Inc: Company Product and Service Offerings
Table 89. Merck & Co. Inc: Company Product Pipeline
Table 90. Merck & Co., Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 91. Merck & Co., Inc: Company Growth Share Analysis 2019 (%)
Table 92. Merck & Co., Inc: Company Recent Developments till Jan, 2021
Table 93. Merck & Co., Inc: Company Recent Developments till Jan, 2021
Table 94. AbbVie Inc.: Company Information
Table 95. AbbVie Inc.: Company Product and Service Offerings
Table 96. Abbvie Inc: Company Product Pipeline
Table 97. AbbVie Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 98. AbbVie Inc.: Company Growth Share Analysis 2019 (%)
Table 99. AbbVie Inc.: Company Recent Developments till Jan, 2021
Table 100. AbbVie Inc.: Company Recent Developments till Jan, 2021
Table 101. Takeda Pharmaceutical: Company Information
Table 102. Takeda Pharmaceutical: Company Product and Service Offerings
Table 103. Takeda Pharmaceuticals: Company Product Pipeline
Table 104. Takeda Pharmaceutical : Company Financial Strengths Analysis 2019 (US$ Million)
Table 105. Takeda Pharmaceutical : Company Growth Share Analysis 2019 (%)
Table 106. Takeda Pharmaceuticals: Company Recent Developments till December,2020
Table 107. Takeda Pharmaceuticals: Company Recent Developments till December,2020
Table 108. Essilor International Company: Company Information
Table 109. Essilor International Company: Company Product and Service Offerings
Table 110. Essilor International Company: Company Financial Strengths Analysis 2019 (US$ Million)
Table 111. Essilor International Company: Company Growth Share Analysis 2019 (%)
Table 112. Essilor International Company: Company Recent Developments till Jan, 2021
Table 113. Essilor International Company: Company Recent Developments till Jan, 2021
Table 114. Teva Pharmaceutical: Company Information
Table 115. Teva Pharmaceutical: Company Product and Service Offerings
Table 116. Teva Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 117. Teva Pharmaceutical: Company Growth Share Analysis 2019 (%)
Table 118. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
Table 119. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
Table 120. Otsuka Holdings Co., Ltd: Company Information
Table 121. Otsuka Holdings Co., Ltd: Company Product and Service Offerings
Table 122. Otsuka Pharmaceuticals: Company Product Pipeline
Table 123. Otsuka Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 124. Otsuka Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 125. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 126. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 127. Bausch Health Companies Inc: Company Information
Table 128. Bausch Health Companies Inc: Company Product and Service Offerings
Table 129. Bausch Health Companies Inc: Company Product Pipeline
Table 130. Bausch Health Companies Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 131. Bausch Health Companies Inc: Company Growth Share Analysis 2019 (%)
Table 132. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
Table 133. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
Table 134. Alcon Inc: Company Information
Table 135. Alcon Inc: Company Product and Service Offerings
Table 136. Alcon Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 137. Alcon Inc: Company Growth Share Analysis 2019 (%)
Table 138. Alcon Inc: Company Recent Developments till Jan, 2021
Table 139. Alcon Inc: Company Recent Developments till Jan, 2021
Table 140. Regeneron Pharmaceuticals, Inc: Company Information
Table 141. Regeneron Pharmaceuticals, Inc: Company Product and Service Benchmarking
Table 142. Regeneron Pharmaceuticals, Inc: Company Product Pipeline
Table 143. Regeneron Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 144. Regeneron Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 145. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
Table 146. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
Table 147. Recipharm publ AB: Company Information
Table 148. Recipharm publ AB: Company Product and Service Benchmarking
Table 149. Recipharm publ AB: Company Financial Strengths Analysis 2019 (US$ Million)
Table 150. Recipharm publ AB: Company Growth Share Analysis 2019 (%)
Table 151. Recipharm publ AB: Company Recent Developments till December,2020
Table 152. Recipharm publ AB: Company Recent Developments till December,2020
Table 153. Beximco Pharmaceuticals Limited: Company Information
Table 154. Beximco Pharmaceuticals Limited: Company Financial Strengths Analysis 2019 (US$ Million)
Table 155. Beximco Pharmaceuticals Limited: Company Growth Share Analysis 2019 (%)
Table 156. Beximco Pharmaceuticals Limited: Company Product and Service Benchmarking
Table 157. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
Table 158. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
Table 159. Edwards Lifesciences: Company Information
Table 160. Edwards Lifesciences: Company Product and Service Offerings
Table 161. Edwards Lifesciences: Company Financial Strengths Analysis 2019 (US$ Million)
Table 162. Edwards Lifesciences: Company Growth Share Analysis 2019 (%)
Table 163. Edwards Lifesciences: Company Recent Developments till Jan, 2021
Table 164. Edwards Lifesciences: Company Recent Developments till Jan, 2021
Table 165. Cooper Companies, Inc.: Company Information
Table 166. Cooper Companies, Inc.: Company Product and Service Offerings
Table 167. Cooper Companies, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 168. Cooper Companies, Inc.: Company Growth Share Analysis 2019 (%)
Table 169. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
Table 170. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
Table 171. Santen Pharmaceutical Co., Ltd: Company Information
Table 172. Santen Pharmaceutical Co., Ltd: Company Product and Service Offerings
Table 173. Santen Pharmaceutical Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 174. Santen Pharmaceutical Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 175. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
Table 176. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
Table 177. Rohto Pharmaceutical: Company Information
Table 178. Rohto Pharmaceutical : Company Product and Service Offerings
Table 179. Rohto Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 180. Rohto Pharmaceutical : Company Growth Share Analysis 2019 (%)
Table 182. Rohto Pharmaceutical: Company Recent Developments till Jan, 2021
Table 183. Carl Zeiss Meditec AG: Company Information
Table 184. Carl Zeiss Meditech AG: Company Product and Service Offerings
Table 185. Carl Zeiss Meditec AG: Company Financial Strengths Analysis 2019 (US$ Million)
Table 186. Carl Zeiss Meditec AG: Company Growth Share Analysis 2019 (%)
Table 187. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
Table 188. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
Table 189. Topcon Corporation: Company Information
Table 190. Topcon Corporation: Company Product and Service Offerings
Table 191. Topcon Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 192. Topcon Corporation: Company Growth Share Analysis 2019 (%)
Table 193. Topcon Corporation: Company Recent Developments till Jan, 2021
Table 194. Topcon Corporation: Company Recent Developments till Jan, 2021
Table 195. Veeva Systems Inc: Company Information
Table 196. Veeva Systems Inc: Company Product and Service Offerings
Table 197. Veeva Systems Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 198. Veeva Systems Inc: Company Growth Share Analysis 2019 (%)
Table 199. Veeva Systems Inc: Company Recent Developments till Jan, 2021
Table 200. Veeva Systems Inc: Company Recent Developments till Jan, 2021
Table 201. Menicon Co., Ltd: Company Information
Table 202. Menicon Co., Ltd: Company Product and Service Offerings
Table 203. Menicon Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 204. Menicon Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 205. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
Table 206. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
Table 207. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Information
Table 208. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Product and Service Offerings
Table 209. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 210. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 211. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 212. Nidek Co. Ltd: Company Information
Table 213. Nidek Co. Ltd: Company Product and Service Offerings
Table 214. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
Table 215. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
Table 216. Glaukos Corporation: Company Information
Table 217. Glaukos Corporation: Company Product and Service Offerings
Table 218. Glaukos Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 219. Glaukos Corporation: Company Growth Share Analysis 2019 (%)
Table 220. Glaukos Corporation: Company Recent Developments till Jan, 2021
Table 221. Glaukos Corporation: Company Recent Developments till Jan, 2021
Table 222. STAAR Surgical: Company Information
Table 223. STAAR Surgical: Company Product and Service Offerings
Table 224. STAAR Surgical: Company Financial Strengths Analysis 2019 (US$ Million)
Table 225. STAAR Surgical: Company Growth Share Analysis 2019 (%)
Table 226. STAAR Surgical: Company Recent Developments till Jan, 2021
Table 227. STAAR Surgical: Company Recent Developments till Jan, 2021
Table 228. Omeros Corporation: Company Information
Table 229. Omeros Corporation: Company Product and Service Offerings
Table 230. Omeros Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 231. Omeros Corporation: Company Growth Share Analysis 2019 (%)
Table 232. Omeros Corporation: Company Recent Developments till Jan, 2021
Table 233. Omeros Corporation: Company Recent Developments till Jan, 2021
Table 234. Aerie Pharmaceuticals, Inc: Company Information
Table 235. Aerie Pharmaceuticals, Inc: Company Product and Service Offerings
Table 236. Aerie Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 237. Aerie Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 238. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 239. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 240. Hoya Corporation: Company Information
Table 241. Hoya Corporation: Company Product and Service Offerings
Table 242. Hoya Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 243. Hoya Corporation: Company Growth Share Analysis 2019 (%)
Table 244. Hoya Corporation: Company Growth Share Analysis 2019 (%)
Table 245. Opsis Therapeutics: Company Information
Table 246. Opsis Therapeutics: Company Product and Service Offerings
Table 247. HORAMA Pharmaceuticals: Company Product Pipeline
Table 248. Opsis Therapeutics: Company Recent Developments till Jan, 2021
Table 249. Opsis Therapeutics: Company Recent Developments till Jan, 2021
Table 250. Alimera Sciences, Inc.: Company Information
Table 251. Alimera Sciences, Inc.: Company Product and Service Offerings
Table 252. Alimera Sciences, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 253. Alimera Sciences, Inc.: Company Growth Share Analysis 2019 (%)
Table 254. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
Table 255. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
Table 256. Bora Pharmaceuticals Co., Ltd: Company Information
Table 257. Bora Pharmaceuticals Co., Ltd: Company Product and Service Offerings
Table 258. Bora Pharmaceuticals Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 259. Bora Pharmaceuticals Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 260. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
Table 261. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
Table 262. IRIDEX Corporation: Company Information
Table 263. IRIDEX Corporation: Company Product and Service Offerings
Table 264. IRIDEX Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
Table 265. IRIDEX Corporation: Company Growth Share Analysis 2019 (%)
Table 266. IRIDEX Corporation: Company Recent Developments till Jan, 2021
Table 267. IRIDEX Corporation: Company Recent Developments till Jan, 2021
Table 268. Eyepoint Pharmaceuticals, Inc: Company Information
Table 269. Eyepoint Pharmaceuticals, Inc: Company Product and Service Offerings
Table 270. Eyepoint Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 271. Eyepoint Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 272. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 273. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 274. KalVista Pharmaceuticals, Inc: Company Information
Table 275. KalVista Pharmaceuticals, Inc: Company Product Pipeline
Table 276. KalVista Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 277. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 278. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 279. Ellex Medical Lasers Limited: Company Information
Table 280. Ellex Medical Lasers Limited: Company Product and Service Offerings
Table 281. Ellex Medical Lasers Limited: Company Financial Strengths Analysis 2019 (US$ Million)
Table 282. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
Table 283. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
Table 284. ThromboGenics NV: Company Information
Table 285. ThromboGenics NV: Company Product and Service Offerings
Table 286. ThromboGenics NV: Company Product Pipeline
Table 287. ThromboGenics NV: Company Financial Strengths Analysis 2019 (US$ Million)
Table 288. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
Table 289. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
Table 290. EyeGate Pharmaceuticals, Inc: Company Information
Table 291. EyeGate Pharmaceuticals, Inc: Company Product Pipeline
Table 292. EyeGate Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 293. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 294. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 295. Ophthalix, Inc: Company Information
Table 296. Ophthalix, Inc: Company Product and Service Offerings
Table 297. Ophthalix, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 298. Ophthalix, Inc: Company Growth Share Analysis 2019 (%)
Table 299. Ophthalix, Inc: Company Recent Developments till Jan, 2021
Table 300. Ophthalix, Inc: Company Recent Developments till Jan, 2021
Table 301. GenSight Biologics SA: Company Information
Table 302. GenSight Biologics SA: Company Product and Service Offerings
Table 303. GenSight Biologics SA: Company Product Pipeline
Table 304. GenSight Biologics SA: Company Financial Strengths Analysis 2019 (US$ Million)
Table 305. GenSight Biologics SA: Company Growth Share Analysis 2019 (%)
Table 306. GenSight Biologics SA: Company Recent Developments till Jan, 2021
Table 307. GenSight Biologics SA: Company Recent Developments till Jan, 2021
Table 308. Neurotech Pharmaceuticals, Inc.: Company Information
Table 309. Neurotech Pharmaceuticals, Inc.: Company Product and Service Offerings
Table 310. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
Table 311. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
Table 312. Phio Pharmaceuticals: Company Information
Table 313. Phio Pharmaceuticals: Company Product Pipeline
Table 314. Phio Pharmaceuticals: Company Financial Strengths Analysis 2019 (US$ Million)
Table 315. Phio Pharmaceuticals: Company Growth Share Analysis 2019 (%)
Table 316. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
Table 317. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
Table 318. Kubota Pharmaceutical Holdings Co., Ltd: Company Information
Table 319. Kubota Pharmaceutical Holdings Co., Ltd: Company Product Pipeline
Table 320. Kubota Pharmaceutical Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
Table 321. Kubota Pharmaceutical Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
Table 322. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 323. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
Table 324. Aerpio Pharmaceuticals, Inc.: Company Information
Table 325. Aerpio Pharmaceuticals, Inc.: Company Product and Service Offerings
Table 326. Aerpio Pharmaceuticals, Inc.: Company Product Pipeline
Table 327. Aerpio Pharmaceuticals, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
Table 328. Aerpio Pharmaceuticals, Inc.: Company Growth Share Analysis 2019 (%)
Table 329. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
Table 330. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
Table 331. Ampio Pharmaceuticals, Inc: Company Information
Table 332. Ampio Pharmaceuticals, Inc: Company Product Pipeline
Table 333. Ampio Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 334. Ampio Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
Table 335. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 336. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
Table 337. Kodiak Sciences Inc: Company Information
Table 338. Kodiak Sciences Inc: Company Product Pipeline
Table 339. Kodiak Sciences Inc: Company Financial Strengths Analysis 2019 (US$ Million)
Table 340. Kodiak Sciences Inc: Company Growth Share Analysis 2019 (%)
Table 341. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
Table 342. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
Table 343. Opsis Therapeutics: Company Information
Table 344. Opsis Therapeutics: Company Product and Service Offerings
Table 345. Opsis Therapeutics: Company Product and Service Offerings
Table 346. Grevis Pharmaceutical: Company Information
Table 347. Grevis Pharmaceutical: Company Product and Service Offerings
Table 348. Grevis Pharmaceutical: Company Product and Service Offerings
Table 349. The Innovexia Life Sciences: Company Information
Table 350. The Innovexia Life Sciences: Company Product and Service Offerings
Table 351. The Innovexia Life Sciences: Company Product and Service Offerings
List of Figures
Figure 1. Structure Of The Eye
Figure 2. AMD Addressable Patient Population (Numbers)
Figure 3. Physiological Changes In Wet And Dry AMD
Figure 4. Glaucoma Addressable Patient Population (Numbers)
Figure 5. Schematic Of Open And Closed Angle Glaucoma
Figure 6. Dry Eye Syndrome Addressable Patient Population (Numbers)
Figure 7. UVEITIS Addressable Patient Population (Numbers)
Figure 8. Prominent Factors Affecting Growth of Ophthalmic Drug Manufacturer Market
Figure 9. Market Drivers for Growth of Ophthalmic Drug Manufacturer Market
Figure 10. Opportunities in the Global Ophthalmic Drug Manufacturer Market
Figure 11. Growth Restrains in the Global Ophthalmic Drug Manufacturer Market
Figure 12. SWOT Analysis of Ophthalmic Drug Manufacturer Market
Figure 13. Porter’s Five Forces Analysis of Ophthalmic Drug Manufacturer Market
Figure 14. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 15. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 16. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 17. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 18. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 19. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 20. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 21. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 22. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 23. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
Figure 24. Johnson & Johnson Vision: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 25. Johnson & Johnson Vision: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 26. Johnson & Johnson Vision: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 27. F. Hoffmann-La Roche AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 28. F. Hoffmann-La Roche AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 29. F. Hoffmann-La Roche AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 30. Pfizer Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 31. Pfizer Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 32. Pfizer Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 33. Novartis AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 34. Novartis AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 35. Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 36. Merck & Co., Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 37. Merck & Co., Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 38. Merck & Co., Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 39. AbbVie Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 40. AbbVie Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 41. AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 42. Takeda Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 43. Takeda Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 44. Takeda Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 45. Essilor International Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 46. Essilor International Company: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 47. Essilor International Company: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 48. Teva Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 49. Otsuka Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 50. Bausch Health Companies Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 51. Bausch Health Companies Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 52. Bausch Health Companies Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 53. Alcon Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 54. Regeneron Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 55. Recipharm publ AB: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 56. Beximco Pharmaceuticals Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 57. Edwards Lifesciences: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 58. Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 59. Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 60. Cooper Companies, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 61. Cooper Companies, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 62. Cooper Companies, Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 63. Santen Pharmaceutical Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 64. Santen Pharmaceuticals: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 65. Rohto Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 66. Rohto Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 67. Rohto Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 68. Carl Zeiss Meditec AG: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 69. Carl Zeiss Meditec AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 70. Carl Zeiss Meditec AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 71. Topcon Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 72. Veeva Systems Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 73. Menicon Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 74. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 75. Glaukos Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 76. STAAR Surgical: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 77. Omeros Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 78. Aerie Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 79. Hoya Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 80. Alimera Sciences, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 81. Alimera Sciences, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 82. Bora Pharmaceuticals Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 83. IRIDEX Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 84. IRIDEX Corporation: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 85. IRIDEX Corporation: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 86. Eyepoint Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 87. KalVista Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 88. Ellex Medical Lasers Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 89. Ellex Medical Lasers Limited: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
Figure 90. Ellex Medical Lasers Limited: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
Figure 91. ThromboGenics NV: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 92. EyeGate Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %) Figure 93. Ophthalix, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 94. GenSight Biologics SA: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 95. Phio Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 96. Kubota Pharmaceutical Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 97. Aerpio Pharmaceuticals, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
AbbVie Inc
Alcon Inc.
Bausch Health
Carl Zeiss Meditec AG
Coopervision Company
Edwards Lifesciences Corp
Essilor International S.A.
Johnson & Johnson Vision Company
Merck & Co.
Novartis AG
Otsuka Pharmaceutical
Pfizer
Regeneron Pharmaceuticals Inc.
Roche Holding AG (Roche)
ROHTO PHARMACEUTICAL CO., LTD.
Santen Pharmaceuticals
Takeda
Teva Pharmaceuticals
Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles
Aerie Pharmaceuticals
Alimera Sciences
Beximco
Bora Pharmaceuticals Co Ltd
Chengdu Kanghong Pharmaceutical
Ellex Medical Lasers Ltd.
EyeGate Pharmaceuticals
EyeGate Pharmaceuticals
Glaukos Corporation
Hoya Corporation
Iridex
Kalvista Pharmaceuticals Inc
Menicon co ltd.
Omeros
OphthaliX /Wize Pharma
Recipharm AB
Staar Surgicals
Thrombo Genics NV
Topcon Corporation
Veeva System Inc
Top 10 Ophthalmic Drugs Manufacturing Companies to Watch
Aerpio Therapeutics
Ampio Pharmaceuticals
Gensight Biologics
Grevis Pharmaceutical
Kodiak Sciences Inc
Kubota Pharmaceutical Holdings Co Ltd
Neurotech
Opsis Therapeutics
Phio Pharmaceuticals Corp
The Innovexia Life Sciences
List of Other Players in the Market
Spark Therapeutics
Abbott Laboratories (Abbott)
Abbvie
Actavis
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allegro Ophthalmics
Allergan
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
Bicycle Therapeutics
BioDiem
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
Inception Sciences, Inc.
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Versant Ventures
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)
List or Organizations Mentioned in the Report
A*STAR Institute for Infocomm Research (Singapore)
Agência Nacional de Vigilância Sanitária (ANVISA)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
Association for Research in Vision and Ophthalmology (ARVO)
Association of British Pharmaceutical Industry (ABPI)
Central Drugs Standard Control Organization (CDSCO)
Council of Europe
Emory University
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
Intellectual Property Appellate Board (India)
International Diabetes Federation
Internet Archive
Japan Patent Office (JPO)
Mayo Clinic
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Novartis Venture Funds (NVF) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Ophthrisi (GSK research unit)
Rinat (Pfizer research unit)
Texas Emerging Technology Fund
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United States Food and Drug Administration (FDA)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031Related reports
Ophthalmic Drugs Market Report 2023-2033
Ophthalmic drugs market was valued at US$29.07 billion in 2022 and is projected to grow at a CAGR of 6.39%...Full DetailsPublished: 13 September 2022Ophthalmic Packaging Market Report 2020-2030
Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends,...
Full DetailsPublished: 01 January 1970Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031
Rising investment in drug R&D by pharmaceutical and biopharmaceutical companies, increasing prevalence of retinal diseases, mounting demand for biologics &...Full DetailsPublished: 11 February 2021Clinical Trial Supply and Logistics Market for Pharma 2021-2031
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain...Full DetailsPublished: 08 July 2021Pharmaceutical Spray Drying Market Report 2021-2031
The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are...Full DetailsPublished: 25 October 2021Ophthalmic Devices Market Report 2022-2032
The number of people who are blind or have poor vision is expected to rise considerably in the coming years....Full DetailsPublished: 19 April 2022Ophthalmic Drugs Market Report to 2030
The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key...Full DetailsPublished: 26 November 2020Top 50 Pharmaceutical Wholesale & Distribution Companies 2021
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead....Full DetailsPublished: 19 July 2021Pharmacy Inventory Management Software Market Report 2020-2030
The increase in the prevalence of non-communicable diseases worldwide has led to an increase in demand for prescription medications.
...Full DetailsPublished: 01 January 1970Global Ophthalmic Surgical Instruments Market 2019-2029
Ophthalmology is a branch of medical sciences that deals with the anatomical and physiological study of eyes such as function,...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Latest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023